Mobile

A single-dose, open-label, randomized, 2-way crossover, clinical pharmacology study of four inhalations of CHF 1535 100/6 NEXT DPI® (fixed combination of beclomethasone dipropionate 100μg plus formote...

Update Il y a 4 ans
Reference: EUCTR2010-024384-40

A single-dose, open-label, randomized, 2-way crossover, clinical pharmacology study of four inhalations of CHF 1535 100/6 NEXT DPI® (fixed combination of beclomethasone dipropionate 100μg plus formoterol fumarate 6 μg) versus the same dose of CHF 1535 100/6 pMDI both administered with charcoal block

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To compare the lung bioavailability of B17MP (active metabolite of BDP) and formoterol after four inhalations using CHF 1535 100/6 NEXT DPI® and CHF 1535 100/6 pMDI using AeroChamber PlusTM spacer, with activated charcoal to block gastrointestinal absorption.

Inclusion criteria

  • Asthma

Links